CLASS ACTION UPDATE for OSH, CABA and AFRM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

ACCESSWIRE 14-Mar-2022 7:15 AM

NEW YORK, NY / ACCESSWIRE / March 14, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

OSH Shareholders Click Here: https://www.zlk.com/pslra-1/oak-street-health-inc-loss-submission-form?prid=24623&wire=1
CABA Shareholders Click Here: https://www.zlk.com/pslra-1/cabaletta-bio-inc-loss-submission-form?prid=24623&wire=1
AFRM Shareholders Click Here: https://www.zlk.com/pslra-1/affirm-holdings-inc-loss-submission-form?prid=24623&wire=1

* ADDITIONAL INFORMATION BELOW *

Oak Street Health, Inc. (NYSE:OSH)

OSH Lawsuit on behalf of: investors who purchased August 6, 2020 - November 8, 2021
Lead Plaintiff Deadline : March 14, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/oak-street-health-inc-loss-submission-form?prid=24623&wire=1

According to the filed complaint, during the class period, Oak Street Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Oak Street maintained relationships with third-party marketing agents likely to provoke law enforcement scrutiny; (2) Oak Street was providing free transportation to federal health care beneficiaries in a manner that would provoke law enforcement scrutiny; (3) these activities may be violations of the False Claims Act; (4) as such, Oak Street was at heightened risk of investigation by the U.S. Department of Justice and/or other federal law enforcement agencies; (5) as a result, Oak Street was subject to adverse impacts related to defense and settlement costs and diversion of management resources; and (6) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Cabaletta Bio, Inc. (NASDAQ:CABA)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.
Lead Plaintiff Deadline : April 29, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cabaletta-bio-inc-loss-submission-form?prid=24623&wire=1

According to the filed complaint, (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Affirm Holdings, Inc. (NASDAQ:AFRM)

This lawsuit is on behalf of all investors who purchased or otherwise acquired Affirm Holdings, Inc. securities on February 10, 2022 after the Company sent a Tweet concerning its Second Quarter 2022 financial results at approximately 1:15 p.m. EST.
Lead Plaintiff Deadline : April 29, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/affirm-holdings-inc-loss-submission-form?prid=24623&wire=1

According to the filed complaint, on February 10, 2022 at approximately 1:15 p.m., Affirm issued a Tweet from its official account in which the Company disclosed certain metrics from its second quarter 2022 financial results. The Tweet, which was published prior to the Company's planned release of its financial results, portrayed a highly successful quarter, which included an increase in revenue of 77%. This caused Affirm's share price to spike nearly 10% in intra-day trading. The Tweet was materially misleading, in that it omitted to disclose the full details of Affirm's second quarter financial results. Affirm deleted the Tweet and released its full second quarter financial results ahead of schedule. The full financial results were lackluster - with the Company posting a loss of $0.57 per share, compared with analyst expectations of $0.37 per share.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE : Levi & Korsinsky, LLP